Booming New Drug Sector Can’t Hide Weakness in Medical Devices: Slowing Medical Device Growth Drags Down Johnson & Johnson (JNJ.US) Q2 Strong Earnings

Zhitong Finance APP reports that, thanks to the strong growth in drugs for treating cancer, inflammatory diseases, and treatment-resistant depression, Johnson & Johnson (JNJ.US) exceeded expectations in its second-quarter sales. The financial report shows that Johnson & Johnson's Q2 revenue reached $25.31 billion, an increase of 6.6% year-on-year, surpassing expectations by $250 million; non-GAAP earnings per share were $2.90, $0.05 above expectations.